OakChart

Anixa Biosciences Inc

ANIXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 10:59 AM ET

2.98-0.08 (-2.61%)
2026-11-11 17:00 CET
Market cap
106.38 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-10.38 USD m
Free cash flow, TTM
-7.38 USD m
EPS diluted, TTM
-0.31
P/E
-
Compare

Price

ANIX against its 20, 50 and 200-day averages
2050200beatearnings
2.503.003.50521K1.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ANIXclose 2.9820-day 3.0050-day 2.90200-day 2.962.9852w low

45.4% under the 52-week high of 5.46 on 9 Dec 2025. 52-week low 2.32 on 11 Jun 2026. Last 15 sessions, 28.3% high to low

Profile

ANIX
52-week range, 21% of the way up
2.325.46

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The Other segment refers to its legacy operations, including patent licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Employees4
IPOOct 07, 1983
Beta0.45
ATR, 14d0.19
Rel volume1.03
Short float4.96%
Insider own5.62%
Inst own15.46%

Snapshot

6 groups

Valuation

Index-
Market Cap103.60M
Enterprise Value88.64M
Income-10.38M
Sales0.00M
Book/sh0.42
Cash/sh0.40
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees4
IPOOct 07, 1983

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B7.12
P/C7.47
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio8.54
Current Ratio8.54
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.31
EPS next Y-0.32
EPS next Q-0.08
EPS this Y7.84%
EPS next Y-1.06%
EPS next 5Y0.99%
EPS past 3/5Y9.05% 5.67%
Sales past 3/5Y- -
EPS Y/Y TTM10.04%
Sales Y/Y TTM-
EPS Q/Q-9.64%
Sales Q/Q-
EarningsSep 11
EPS/Sales Surpr.0.00% -

Ownership

Insider Own5.62%
Insider Trans9.55%
Inst Own15.46%
Inst Trans1.12%
ROA-63.45%
ROE-66.84%
ROIC-71.11%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-0.58%
SMA502.73%
SMA2000.55%
Trades-

Technical

Shs Outstand34.58M
Shs Float32.81M
Short Float4.96%
Short Ratio5.91
Short Interest1.63M
52W High5.46 -45.39%
52W Low2.32 28.45%
Volatility7.26% 6.70%
ATR (14)0.19
RSI (14)48.84
Beta0.45
Rel Volume1.03
Avg Volume275.40K
Volume75,917

Performance

Perf Week-9.15%
Perf Month11.61%
Perf Quarter-6.88%
Perf Half Y2.76%
Perf YTD-4.49%
Perf Year-35.22%
Perf 3Y1.71%
Perf 5Y-36.60%
Perf 10Y-48.62%
Recom1.00
Target Price9.67
Prev Close3.06
Price2.98
Change %-2.61%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Mar 21, 2025InitiatedMMaxim GroupBuy$10+235.6%
Dec 23, 2022InitiatedCChardan Capital MarketsBuy$8+168.5%
Apr 12, 2021InitiatedHH.C. WainwrightBuy$11+269.1%

Peers

Mkt cap
TickerCompanyMkt cap
GLSIGreenwich LifeSciences Inc242.34M
ELTXElicio Therapeutics Inc43.59M
OSTXOS Therapies Inc45.47M
SLSSELLAS Life Sciences Group Inc1.71B
INOInovio Pharmaceuticals Inc140.78M
IMNNImunon Inc4.43M
NKTXNkarta Inc97.16M
ALLOAllogene Therapeutics Inc311.61M
MRNAModerna Inc99.96B
BNTXBioNTech SE ADR21.59B

Insider trading

latest 14 of 23
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
KUMAR AMITChief Executive OfficerOct 30 '26Buy3.175,00015,850685,000Nov 02 08:54 AM
Titterton Lewis H jrDirectorOct 23 '26Buy2.988,00023,8401,054,003Oct 26 04:15 PM
KUMAR AMITChief Executive OfficerOct 22 '26Buy2.728,00021,760680,000Oct 22 05:44 PM
Catelani MichaelPresident, COO, & CFOSep 30 '26Buy2.845,50015,62050,000Sep 30 10:25 AM
KUMAR AMITChief Executive OfficerSep 24 '26Buy2.787,00019,460672,000Sep 28 08:45 AM
Baskies Arnold MDirectorSep 24 '26Buy2.765,00013,800140,572Sep 28 08:30 AM
Titterton Lewis H jrDirectorSep 23 '26Buy2.6949,036131,9071,046,003Sep 25 08:39 AM
KUMAR AMITChief Executive OfficerSep 10 '26Buy2.753,0008,250665,000Sep 14 09:45 AM
Titterton Lewis H jrDirectorSep 10 '26Buy2.7310,00027,300996,967Sep 14 09:15 AM
KUMAR AMITChief Executive OfficerSep 10 '26Buy2.765,00013,800662,000Sep 11 08:00 AM
KUMAR AMITChief Executive OfficerJul 31 '26Buy3.475,00017,350657,000Aug 03 08:45 AM
Baskies Arnold MDirectorJul 27 '26Option Exercise3.136,00018,780141,000Jul 29 09:14 AM
KUMAR AMITChief Executive OfficerJul 27 '26Buy3.445,00017,200652,000Jul 28 10:20 AM
KUMAR AMITChief Executive OfficerJul 27 '26Buy3.373,18810,744647,000Jul 27 03:25 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 206
  • Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026 (PR Newswire) +7.36%
  • Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
  • Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference (PR Newswire) -5.99%
  • Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
  • Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial (PR Newswire) -5.46%
  • Loading…
  • Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 (PR Newswire)
  • Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board (PR Newswire)
  • Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV (PR Newswire)
  • Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 (PR Newswire)
  • Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy (PR Newswire)
  • Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
  • Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology (PR Newswire)
  • Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date (PR Newswire) -6.73%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-09-11-0.083-0.083-0.0850.000.002
2026Q22026-06-05-0.073-0.085-0.0750.000.002
2026Q12026-03-13-0.080-0.089-0.0770.000.004
2025Q42026-01-07-0.081-0.088-0.0820.000.003
2025Q32025-09-12-0.081-0.077-0.0700.000.003
2025Q22025-06-06-0.089-0.093-0.0870.000.003
2025Q12025-03-14-0.100-0.080-0.0990.000.002
2024Q42025-01-01-0.090-0.085-0.0900.000.002
2024Q32024-09-06-0.100-0.085-0.1020.000.002
2024Q22024-06-07-0.100-0.110-0.0980.000.001
2024Q12024-03-08-0.100-0.090-0.1040.000.001
2023Q42024-01-03-0.090-0.090-0.0870.000.001
2023Q32023-09-08-0.080-0.090-0.0810.000.002
2023Q22023-08-29-0.095--0.0740.10-2
2023Q12023-06-05-0.080--0.0750.00-1
2022Q42023-01-04-0.130--0.1130.00-2

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.580-0.710-0.5890.280.25
2020FY-0.440-0.470-0.4510.000.00
2021FY-0.450-0.410-0.4530.510.50
2022FY-0.450-0.345-0.4480.000.00
2023FY-0.320-0.320-0.3170.200.20
2024FY-0.393-0.395-0.3940.000.00
2025FY-0.343-0.356-0.3420.000.00
2026FY--0.313--0.00
2027FY--0.317--0.00
2028FY--0.330--0.00
2029FY--0.380---
2030FY-1.640--82.10

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-09-212000.000.000.00
2026Q4S2026-09-181000.000.000.00
2026Q4S2026-09-112000.000.000.00
2026Q4S2026-06-102000.000.000.00
2026Q4S2026-06-051000.000.000.00
2026Q4S2026-05-171000.000.000.00
2026Q4S2026-03-212000.000.000.00
2026Q4S2026-03-133000.000.000.00
2026Q4S2026-02-063000.000.000.00
2026Q4S2026-01-122000.000.000.00
2026Q4S2026-01-071000.000.000.00
2026Q4S2025-12-191000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00

Estimate history

EPS, annual-0.58-0.794-0.589-0.451-0.453-0.448-0.317-0.394-0.337-0.31
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.102-0.09-0.099-0.087-0.07-0.082-0.077-0.075-0.076
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.3631.1130.2500.51300.21000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual16.60318.90920.33224.24930.05130.91431.14532.19533.01234.585
Period201720182019202020212022202320242025MRQ
Shares, quarterly32.14632.19532.19532.21132.82233.01233.46333.92334.585
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.210.000.510.000.251.11
Cost of Goods Sold Incl. D&A0.040.040.040.050.040.390.090.631.09
Gross Profit-0.04-0.04-0.040.16-0.040.13-0.09-0.380.02
Selling, General and Administrative Excl. Other10.9411.6613.7911.1813.8313.269.8911.0913.72
Research and Development4.835.076.404.776.706.194.385.436.81
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-10.98-11.70-13.83-11.01-13.88-13.14-9.98-11.47-13.71
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.420.58
Net Income Before Taxes-10.47-11.03-12.70-9.93-13.77-13.13-10.09-11.82-14.24
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-10.47-11.03-12.70-9.93-13.77-13.13-10.09-11.82-14.24
Net Income From Continuing Operations-10.38-10.93-12.55-9.81-13.60-12.95-10.02-11.65-14.00
Net Income-10.38-10.93-12.55-9.81-13.60-12.95-10.02-11.65-14.00
EPS (Recurring)-0.30-0.34-0.39-0.32-0.45-0.45-0.45-0.57-0.77
EPS (Basic, Before Extraordinaries)-0.31-0.34-0.39-0.32-0.45-0.45-0.45-0.59-0.79
EPS (Diluted)-0.31-0.34-0.39-0.32-0.45-0.45-0.45-0.59-0.79
EBITDA-10.94-11.66-13.79-10.96-13.83-13.08-9.89-11.00-13.36
Non-Operating Income (Expense)0.510.671.131.080.100.01-0.110.070.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.013.814.784.746.667.504.145.718.90
Price To Sales Ratio---466.18-265.99-306.3564.16
Gross Margin---78.10-24.88--153.021.69
Operating Margin----5,243.33--2,563.06--4,588.50-1,232.01
Net Margin----4,671.90--2,527.69--4,658.82-1,258.07
Shares Outstanding34.5833.0132.1931.1530.9130.0524.2520.3318.91
Market Capitalization106.38106.38112.6398.18171.71142.8649.0178.2075.72

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.010.010.010.01
Gross Profit-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01
Selling, General and Administrative Excl. Other2.732.642.712.872.432.993.383.15
Research and Development1.331.261.101.141.051.321.551.48
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.74-2.65-2.72-2.88-2.44-3.00-3.39-3.16
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-2.62-2.54-2.58-2.72-2.28-2.81-3.21-2.91
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.62-2.54-2.58-2.72-2.28-2.81-3.21-2.91
Net Income From Continuing Operations-2.61-2.52-2.56-2.69-2.26-2.79-3.18-2.88
Net Income-2.61-2.52-2.56-2.69-2.26-2.79-3.18-2.88
EPS (Recurring)-0.08-0.07-0.08-0.08-0.07-0.09-0.10-0.09
EPS (Basic, Before Extraordinaries)-0.08-0.07-0.08-0.08-0.07-0.09-0.10-0.09
EPS (Diluted)-0.08-0.07-0.08-0.08-0.07-0.09-0.10-0.09
EBITDA-2.73-2.64-2.71-2.87-2.43-2.99-3.38-3.15
Non-Operating Income (Expense)0.110.110.130.150.160.190.170.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.670.640.800.910.850.991.051.08
Shares Outstanding34.5833.9233.4633.0132.8232.2132.1932.19
Market Capitalization106.38100.58101.47135.9598.5789.8393.37112.63

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments15.1719.9223.8429.6935.739.065.845.066.84
Short Term Receivables0.000.170.270.000.000.000.070.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.711.261.240.510.280.310.180.480.17
Total Current Assets15.8921.3625.3630.2036.009.376.095.547.01
Net Property, Plant & Equipment0.190.230.170.210.250.050.200.070.05
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.00-0.000.841.75
Other Assets0.000.000.000.000.000.030.000.000.00
Total Assets16.0821.5925.5230.4136.269.456.296.458.81
Short Term Debt Incl. Current Port. of LT Debt0.040.030.050.050.040.060.000.000.00
Accounts Payable0.170.530.210.270.140.230.590.580.48
Other Current Liabilities1.761.951.771.731.090.900.900.680.41
Total Current Liabilities1.972.502.032.041.271.191.481.270.89
Long Term Debt0.160.200.120.170.220.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities2.132.702.152.211.491.191.481.270.89
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity15.1620.0024.3429.0535.448.765.245.437.92
Total Shareholders Equity15.1620.0024.3429.0535.448.765.245.437.92
Accumulated Minority Interest-1.21-1.11-0.97-0.85-0.67-0.50-0.42-0.250.00
Total Equity13.9518.8923.3728.2034.778.264.815.187.92
Total Liabilities & Stockholders Equity16.0821.5925.5230.4136.269.456.296.458.81
Book Value Per Share0.460.620.780.941.180.360.260.290.48
Tangible Book Value Per Share0.460.620.780.941.180.360.260.240.37
Full-Time Employees455554887
Price to Book Ratio7.315.174.045.963.925.6515.0314.094.30
Return on Assets-58.01-53.29-35.08-40.78-56.68-127.24-182.81-183.42-69.37
Return on Equity-62.16-56.63-36.76-42.17-58.62-143.15-218.31-209.56-112.43
Return on Invested Capital-71.31-62.15-40.11-46.52-36.33-114.35-222.47-257.53-63.22
Quick Ratio8.088.5412.5014.8328.347.884.114.387.89
Current Ratio8.088.5412.5014.8328.347.884.114.387.89

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-10.47-11.03-12.70-9.93-13.77-13.13-10.09-11.82-14.24
Depreciation0.040.040.040.050.040.060.090.470.34
Other Funds (Non Cash)3.053.674.804.746.758.054.296.139.56
Funds from Operations-7.38-7.33-7.86-5.15-6.98-5.02-5.72-5.22-4.34
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.010.150.53-1.060.480.08-0.460.480.07
Cash from Operating Activities-7.38-7.17-7.33-6.21-6.49-4.94-6.18-4.74-4.27
Capital Expenditures0.000.000.000.000.000.00-0.02-0.18-0.04
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.040.000.000.00
Purchase or Sale of Investments2.064.874.28-5.60-10.73-3.95-0.29-0.351.50
Purchase of Investments-42.08-44.36-63.77-44.41-22.49-16.50-5.01-3.85-4.25
Sale Or Maturity of Investments44.1449.2368.0538.8111.7612.554.723.505.75
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities2.064.874.28-5.60-10.73-3.92-0.31-0.531.46
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.222.283.420.370.4531.579.415.692.53
Repurchase of Common Pref Stock0.000.00-0.010.000.000.000.000.000.00
Sale of Common Pref Stock5.222.283.420.370.4531.579.415.692.53
Proceedsfrom Stock Options5.262.382.960.000.0031.139.285.572.47
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.010.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities5.222.283.420.370.4531.579.415.702.53
Net Change in Cash-0.10-0.030.36-11.45-16.7722.712.930.44-0.28
Free Cash Flow-7.38-7.17-7.33-6.21-6.49-4.94-6.19-4.92-4.31
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments13.8613.6914.2015.1716.0315.60
Short Term Receivables0.000.060.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.050.950.850.711.421.17
Total Current Assets14.9114.6915.0515.8917.4516.77
Net Property, Plant & Equipment0.160.170.180.190.200.21
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets15.0714.8715.2316.0817.6516.98
Short Term Debt Incl. Current Port. of LT Debt0.050.040.040.040.040.04
Accounts Payable0.280.250.150.170.280.28
Other Current Liabilities1.421.211.051.761.751.57
Total Current Liabilities1.751.501.241.972.071.89
Long Term Debt0.130.140.150.160.170.18
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.871.641.392.132.242.07
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity14.4714.4715.0815.1616.5916.07
Total Shareholders Equity14.4714.4715.0815.1616.5916.07
Accumulated Minority Interest-1.27-1.25-1.23-1.21-1.18-1.16
Total Equity13.2013.2213.8513.9515.4114.91
Total Liabilities & Stockholders Equity15.0714.8715.2316.0817.6516.98
Book Value Per Share0.420.430.450.460.510.50
Tangible Book Value Per Share0.420.430.450.460.510.50
Full-Time Employees---4--
Price to Book Ratio7.316.666.628.176.135.03
Return on Assets-63.45-63.02-60.39-58.01-54.81-58.71
Return on Equity-66.84-65.70-62.61-62.16-57.94-61.14
Return on Invested Capital-17.85-17.22-16.84-17.59-13.47-17.17
Quick Ratio8.549.7912.188.088.458.89
Current Ratio8.549.7912.188.088.458.89

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-2.62-2.54-2.58-2.72-2.28-2.81
Depreciation0.010.010.010.010.010.01
Other Funds (Non Cash)0.650.690.840.860.841.16
Funds from Operations-1.96-1.84-1.73-1.85-1.43-1.64
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.190.10-0.880.60-0.080.14
Cash from Operating Activities-1.77-1.74-2.61-1.25-1.51-1.50
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-0.240.421.230.65-0.832.34
Purchase of Investments-9.78-12.11-12.53-7.66-11.77-11.93
Sale Or Maturity of Investments9.5312.5313.768.3110.9414.27
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.240.421.230.65-0.832.34
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.941.251.690.351.930.02
Repurchase of Common Pref Stock0.000.000.000.000.000.01
Sale of Common Pref Stock1.941.251.690.351.930.00
Proceedsfrom Stock Options1.941.251.620.451.920.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.941.251.690.351.930.02
Net Change in Cash-0.08-0.070.30-0.25-0.410.86
Free Cash Flow-1.77-1.74-2.61-1.25-1.51-1.50

Revenue breakdown

Pharmaceutical Preparations2024: 210.00K
United States2024: 210.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.96%1.6M32.8M277.25K
2026-10-155.06%1.7M32.8M296.93K
2026-09-304.12%1.4M32.8M300.11K
2026-09-153.21%1.1M32.8M299.43K
2026-08-313.09%1.0M32.2M256.80K
2026-08-143.04%1.0M32.2M223.78K
2026-07-313.39%1.1M32.2M217.18K
2026-07-152.68%0.9M32.2M184.57K
2026-06-302.75%0.9M32.2M156.64K
2026-06-152.50%0.8M32.2M114.10K
2026-05-293.20%1.0M31.7M108.60K
2026-05-153.10%1.0M31.7M107.69K
2026-04-303.27%1.0M31.7M121.82K
2026-04-153.29%1.0M31.7M136.15K
2026-03-313.62%1.1M31.7M160.80K
2026-03-133.63%1.2M31.7M205.38K
2026-02-273.66%1.2M31.6M303.91K
2026-02-134.06%1.3M31.6M315.76K
2026-01-303.76%1.2M31.6M309.14K
2026-01-153.66%1.2M31.6M299.73K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.001.450.507.34112.000.000.725-0.0370.002
call5.000.000.050.052.1401430.000.111-0.0100.001
call7.500.000.250.003.2830.000.000.081-0.0130.001
put2.500.000.500.304.24660.000.00-0.275-0.0370.002
put5.000.153.900.0013.4710.000.00-0.890-0.0110.001
put7.502.656.400.0014.8540.000.00-0.918-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-024Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-07-31SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-284Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-04-30SEC
2026-03-118-KCurrent report2026-03-10SEC
2026-03-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-01-31SEC
2026-02-098-KCurrent report2026-02-09SEC
2026-01-294Statement of changes in beneficial ownership of securities2026-01-28SEC
2026-01-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-01-28SEC
2026-01-12S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-01-1210-KAnnual report pursuant to Section 13 or 15(d)2025-10-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1061.45K300
2026-09230.14K700
2026-080000
2026-07139.80K800
2026-0659.99K200
2026-050000
2026-040000
2026-030000
2026-020000
2026-0130.40K100
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC3.91%
Laird Norton Wetherby Trust Company, LLC1.70%
UBS Group AG1.69%
D.A. DAVIDSON & CO.1.42%
GEODE CAPITAL MANAGEMENT, LLC0.98%
MARSHALL WACE, LLP0.97%
BlackRock, Inc.0.59%
VANGUARD FIDUCIARY TRUST CO0.57%
STATE STREET CORP0.47%
GSA CAPITAL PARTNERS LLP0.35%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.75%
VANGUARD EXTENDED MARKET INDEX FUND1.04%
Fidelity Extended Market Index Fund0.48%
iShares Micro-Cap ETF0.32%
Fidelity Total Market Index Fund0.15%
Fidelity Series Total Market Index Fund0.14%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.06%
VANGUARD BALANCED INDEX FUND0.05%
Schwab Total Stock Market Index Fund0.04%
1290 VT Micro Cap Portfolio0.02%

OakChart. ANIX. Cached 15 minutes.